Liquidia Technologies is applying its novel PRINT® technology toward internal, licensed, and co-development opportunities, including:

  • Internal development of LIQ861 for inhaled and LIQ865 for pain relief
  • Ophthalmic therapeutics through spin-out company Envisia Therapeutics
  • Partnerships with biopharmaceutical companies such as GlaxoSmithKline

* Additional Programs In Pre-Clinical Development
† Liquidia Spin-Out Independent Company

© 2017 Liquidia Technologies